Determination of human absorbed dose of cocktail of 153Sm/177Lu-EDTMP, based on biodistribution data in rats

Ranjbar, Hassan; Bahrami-Samani, Ali; Yazdani, Mehrdad; Ghannadi‐Maragheh, Mohammad

doi:10.1007/s10967-015-4324-x

Cited by 8 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A radiopharmaceutical can act either alone as a radionuclide-like iodine-131 or as an attached radionuclide to a carrier molecule for targeting the organ of interest. Treatment with radiopharmaceuticals causes the injection dose to be absorbed mainly into the target tumor, resulting in a very small amount absorbed by the surrounding tissues [15].…”

Section: Radionuclide Targeted Therapymentioning

confidence: 99%

The radio-europium impurities in [153Sm]-EDTMP production: a review of isolation methods

Naseri

Charkhi

Salek

et al. 2021

Nuclear Medicine Communications

View full text Add to dashboard Cite

Many human cancers predominantly metastasize to the bone which causes bone pain and other symptoms. However, the management of bone metastases is challenging. Radionuclide therapy using low-energy beta-emitting radionuclides has yielded encouraging results. The aim of this therapy is to deliver the maximum dose to the metastatic sites but a minimal dose to the normal tissue. Samarium-153 [153Sm]Sm-Ethylenediamine tetramethylene phosphonate (EDTMP) is an FDA and European Medicine Agency approved (Quadramet) radionuclide and is widely used for bone pain palliation. 153Sm is reactor produced, and the presence of europium impurities is thus unavoidable. This in turn causes an increase in the hospital radioactive waste burden and in radiation absorbed doses to the patients, and therefore it is a concern. The effective removal of these impurities is thus highly desirable before its administration to the patients. In this article, we present a detailed review of the various methods described in the literature for separation of 153Sm and Eu, that is solvent extraction, ion-exchange chromatography, electrochromatography, electrochemical separation and supported ionic liquid phase.

show abstract

Section: Radionuclide Targeted Therapymentioning

confidence: 99%

The radio-europium impurities in [153Sm]-EDTMP production: a review of isolation methods

Naseri

Charkhi

Salek

et al. 2021

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…After calculating the accumulated activities by computing the area under the curves these calculated accumulated activities were extrapolated to human by the proposed method of Sparks and Aydogan [13,14]. Which in the above formula HO indicates Human Organ, AO indicates Animal Organ, HB indicates Human Body and AB indicates Animal Body.…”

Section: Dosimetric Studiesmentioning

confidence: 99%

Human Absorbed Dose Evaluation of [177Lu]Lu-IBA as a Bone Palliative Candidate

Ranjbar

Pourhabib

2021

Nuklearmedizin

Self Cite

View full text Add to dashboard Cite

The role of lutetium-177 among bone-seeking radionuclides in targeted therapy is noteworthy. The clinical pharmacokinetics of ibandronate (IBA) indicates that this bisphonate has powerful bone mineral affinity. The aim of this study was to evaluate of [177Lu]Lu-IBA efficacy as a new compound.The [177Lu]Lu-IBA was prepared by radiolabeling of IBA ligand to 177LuCl3 that was obtained by thermal neutron irradiation of enriched Lu2O3 sample. Produced [177Lu]Lu-IBA with high radiochemical purity was administered intravenously to mice. Biodistribution data were collected at 1, 4, 24, 48 h and 7 d post injections. With calculating accumulated activities in each organ and extrapolating mouse’s organs to human’s organs by the RADAR method and using OLINDA/EXM software the injected dose in various human organs was achieved.[177Lu]Lu-IBA was produced with radiochemical purity nearly 96 %. Its biodistribution data showed the high uptake and durability in the skeletal tissues without significant uptake in other major organs.The results showed that [177Lu]Lu-IBA has considerably good properties as a bone-seeking radiopharmaceutical and therefore can be a candidate for bone pain palliative therapy in skeletal metastases; however, further biological studies are still needed.

show abstract

“…Kemudian proses bone scan pada umumnya dilakukan 3 jam setelah injeksi radiofarmaka Tc-MDP dengan kamera gamma, sehingga tingginya distribusi aktivasi radiofarmaka di tulang pada 4 jam setelah injeksi dilihat pada Gambar 3 menunjukan pencitraan yang cukup baik [14] [15] . Metode ekstrapolasi ini telah banyak dilakukan pada studi-studi radiofarmaka baru seperti yang dilakukan Nur Rahmah dkk [17], H. Rezaeejam dkk [18], H. Ranjbar dkk [19], dan S. Shanehsazzadeh dkk [20]. Penimbunan dosis injeksi radiofarmaka 99m Tc-MDP per gram organ manusia terakumulasi pada organ target yaitu tulang ditunjukkan pada Gambar 3 didapatkan 26,79%; 52,83%; 30,31%; dan 14,46% pada waktu berturut-turut 2, 4, 6, dan 24 jam.…”

Section: Uji Biodistribusiunclassified

STUDI AWAL ESTIMASI DOSIS INTERNAL 99mTc-MDP HASIL PRODUKSI PSTNT-BATAN PADA MANUSIA UNTUK DETEKSI METASTASIS DAN INFLAMASI TULANG BERBASIS UJI BIODISTRIBUSI HEWAN MODEL MENCIT

Islami

Hidayati

Wibawa

et al. 2019

gnd

View full text Add to dashboard Cite

STUDI AWAL ESTIMASI DOSIS INTERNAL 99mTc-MDP HASIL PRODUKSI PSTNT-BATAN PADA MANUSIA UNTUK DETEKSI METASTASIS DAN INFLAMASI TULANG BERBASIS UJI BIODISTRIBUSI HEWAN MODEL MENCIT. Kanker adalah sel abnormal yang dapat menyebar sampai ke tulang. Pemeriksaan dapat dilakukan dengan bone-scan menggunakan radiofarmaka. PSTNT-BATAN Bandung melakukan penelitian radiofarmaka penyidik tulang yaitu MDP yang dapat ditandai dengan radionuklida teknesium-99m. Penelitian ini bertujuan memperoleh estimasi dosis internal radiofarmaka 99mTc-MDP sebagai penyidik metastasis dan inflamasi tulang untuk manusia berdasarkan biodistribusi radiofarmaka 99mTc-MDP produksi PSTNT-BATAN. Metode penelitian ini, uji biodistribusi dari penandaan MDP dengan teknesium-99m dengan interval waktu 2,4,6, dan 24 jam setelah penyuntikan melalui intravena ekor pada 12 hewan model mencit normal dengan dosis injeksi 5,44 MBq tiap mencit dengan kemurnian 98,49%±25,37.Hasil uji biodistribusi didapatkan persentase dosis injeksi pergram organ hewan yang dikonversi menjadi persentase dosis injeksi pergram organ manusia yang diinput pada software OLINDA/EXM untuk mendapatkan residence time dan estimasi dosis internal. Hasil estimasi dosis menggunakan OLINDA/EXM diperoleh nilai total estimasi dosis efektif 99mTc-MDP (mSv/MBq) untuk laki-laki dewasa 1,87E-03 sedangkan untuk wanita dewasa bernilai 2,24E-03. Hasil estimasi dosis radiofarmaka 99mTc-MDP produksi PSTNT-BATAN ini dapat digunakan sebagai panduan dosis organ pada saat akan diinjeksikan pada manusia.

show abstract

Determination of human absorbed dose of cocktail of 153Sm/177Lu-EDTMP, based on biodistribution data in rats

Cited by 8 publications

References 11 publications

The radio-europium impurities in [153Sm]-EDTMP production: a review of isolation methods

The radio-europium impurities in [153Sm]-EDTMP production: a review of isolation methods

Human Absorbed Dose Evaluation of [177Lu]Lu-IBA as a Bone Palliative Candidate

STUDI AWAL ESTIMASI DOSIS INTERNAL 99mTc-MDP HASIL PRODUKSI PSTNT-BATAN PADA MANUSIA UNTUK DETEKSI METASTASIS DAN INFLAMASI TULANG BERBASIS UJI BIODISTRIBUSI HEWAN MODEL MENCIT

Contact Info

Product

Resources

About